Title: Clinical Efficacy and Safety Evaluation of Tongxinluo Capsule Treating Migraine
Abstract: Objective: To investigate the clinical efficacy and safety evaluation analysis of Tongxinluo Capsule treating migraine and to provide a reference for clinical diagnosis and treatment. Methods: 62 patients with migraine were randomly divided according to the random number table into the control group( n = 31) and observation group( n = 31). All patients were given vitamin B1,vitamin B12 and oryzanol conventional treatment. The control group was given Flunarizine Hydrochloride Capsules treatment and the observation group given Tongxinluo Capsule treatment. 4 weeks was a course of treatment. The efficacy,NO,ET- 1 and adverse reactions after two courses were evaluated. Results: The total effective rate( 87. 10%) in the observation group was significantly higher than that( 64. 52%) of the control group after treatment and there was significant difference( P 0. 05). After treatment,ET- 1 levels were significantly lower than those before treatment and the difference was statistically significant( P 0. 05). In the observation group after treatment,ET- 1 levels( 63. 24 ± 12. 23) μmol / L was significantly lower than( 70. 09 ± 13. 09) μmol / L of the control group and the difference was statistically significant( P 0. 05). After treatment,NO content was significantly lower than those before treatment in each group and the difference was statistically significant( P 0. 05). NO levels after treatment in the observation group was( 73. 91 ± 10. 37) ng / L lower than( 78. 27 ± 11. 29) ng / L of the control group and the difference was not statistically significant( P 0. 05). Two groups' adverse reactions had no significant difference( P 0. 05). Conclusion: Tongxinluo Capsule treating migraine has significant effect and fewer adverse reactions. It is safe,reliable and worthy of promotion.
Publication Year: 2014
Publication Date: 2014-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot